SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses of these vaccines and the development of new variant-derived ones(1–4). SARS-CoV-2 booster immunizations in humans primarily recruit p...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsoussi, Wafaa B., Malladi, Sameer K., Zhou, Julian Q., Liu, Zhuoming, Ying, Baoling, Kim, Wooseob, Schmitz, Aaron J., Lei, Tingting, Horvath, Stephen C., Sturtz, Alexandria J., McIntire, Katherine M., Evavold, Birk, Han, Fangjie, Scheaffer, Suzanne M., Fox, Isabella F., Parra-Rodriguez, Luis, Nachbagauer, Raffael, Nestorova, Biliana, Chalkias, Spyros, Farnsworth, Christopher W., Klebert, Michael K., Pusic, Iskra, Strnad, Benjamin S., Middleton, William D., Teefey, Sharlene A., Whelan, Sean P.J., Diamond, Michael S., Paris, Robert, O’Halloran, Jane A., Presti, Rachel M., Turner, Jackson S., Ellebedy, Ali H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516848/
https://www.ncbi.nlm.nih.gov/pubmed/36172127
http://dx.doi.org/10.1101/2022.09.22.509040

Ejemplares similares

Ejemplares similares